CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 80 enrolled
Drug / intervention
Losartan potassium/Hydrochlorothiazide +1 moredrug
Likely dose
Losartan potassium/Hydrochlorothiazide 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01149473
NCT01149473Phase 1Completed
CompareCT.gov

A Relative Bioavailability Study of Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets Under Non-Fasting Conditions

Teva Pharmaceuticals USA·interventional·Posted Jun 23, 2010·Updated Aug 20, 2024

In Brief

A Phase 1 clinical trial evaluating Losartan potassium/Hydrochlorothiazide for Healthy. Completed, enrolled 80 participants across 1 site.

Detailed Summary

The objective of this study is to compare the relative bioavailability of Losartan potassium/Hydrochlorothiazide 100/25 mg tablets (manufactured by Teva Pharmaceutical Industries, Ltd. and distributed by Teva Pharmaceuticals USA) with that of Hyzaar® 100/25 mg tablets (Merck) in healthy, adult, non-smoking subjects under non-fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 23, 2010
Enrollment StartMar 1, 2004
Primary CompletionApr 1, 2004
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16.0 years ago

Interventions

Losartan potassium/Hydrochlorothiazidedrug

100/25 mg Tablets

Losartan potassium/Hydrochlorothiazidedrug

100/25 mg Tablets